# Emtricitabine/Tenofovir Alafenamide as Salvage ART

> **NCT02556333** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** FTC/TAF

## Key facts

- **NCT ID:** NCT02556333
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-16
- **Primary completion:** 2016-08-16
- **Final completion:** 2016-08-16
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556333, "Emtricitabine/Tenofovir Alafenamide as Salvage ART". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02556333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*